Tag: 340B Drug Discount Program
Manufacturers are struggling with how best to respond to the increasing volume of 340B self-reporting offers and checks from Covered Entities. In response, CiiTA is pleased to introduce the Manufacturer 340B Self-Reporting Assistance offering. CiiTA assists manufacturers by providing guidance and data analysis to support investigation into events triggering self-reporting letters and refund checks. Our…
Read MorePORTLAND, Ore. – April 25, 2016 — CiiTA founder and managing partner Jason Hardaway is invited to speak at the upcoming third-annual National Leadership Summit on 340B in Washington, D.C. on May 17, 2016. This summit is the annual opportunity for stakeholders to engage in meaningful and transparent dialogue to ensure the 340B program’s future…
Read MoreThe P&T (Pharmacy and Therapeutics) Community online journal has published a response by CiiTA’s Managing Partner, Jason Hardaway, to their October 2015 report by Stephen Barlas about Congress’s 340B Program omnibus guidance issued by the Health Resources and Services Administration (HRSA). Mr. Hardaway’s article, titled 340B Program Puts Manufacturers At Risk of Duplicate Drug Discounts, addresses the material and financial risk of duplicate…
Read MoreDevelop Your 340B Strategy
CiiTA has, through extensive experience, developed a set of best practices to help guide you through the creation of your 340B strategy. Download our process document to facilitate the development of your strategy.